Cart
sales@molnova.com
Salmeterol xinafoate
CAS No. 94749-08-3
Salmeterol xinafoate( GR-33343X xinafoate )
Catalog No. M16788 CAS No. 94749-08-3
A long-acting beta2-adrenergic receptor agonist (Ki=1.5 nM) used clinically to treat asthma and maintenance of COPD.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 39 | In Stock |
|
| 10MG | 65 | In Stock |
|
| 25MG | 129 | In Stock |
|
| 50MG | 215 | In Stock |
|
| 100MG | 356 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameSalmeterol xinafoate
-
NoteResearch use only, not for human use.
-
Brief DescriptionA long-acting beta2-adrenergic receptor agonist (Ki=1.5 nM) used clinically to treat asthma and maintenance of COPD.
-
DescriptionA long-acting beta2-adrenergic receptor agonist (Ki=1.5 nM) used clinically to treat asthma and maintenance of COPD. Asthma Approved(In Vitro):Salmeterol (0.001-25 μM) inhibits human T lymphocyte proliferation.(In Vivo):Salmeterol (0.16 mg/kg), Formoterol (0.32 mg/kg) and combined treatment have therapeutic effects in mice with chronic obstructive pulmonary disease (COPD).
-
In VitroSalmeterol (0.001-25 μM) inhibits human T lymphocyte proliferation. Cell Proliferation Assay Cell Line:Human T lymphocytes (THP-1 cells) Concentration:0.001, 0.01, 0.05, 0.2, 1, 5, and 25 μM Incubation Time:Result:The proliferation of Th2 cells was inhibited in a concentration dependent manner.
-
In VivoSalmeterol (0.16 mg/kg), Formoterol (0.32 mg/kg) and combined treatment have therapeutic effects in mice with chronic obstructive pulmonary disease (COPD). Animal Model:Male C57BL/6 mice (6-8 weeks old, body weight: 32-35 g)Dosage:Salmeterol (0.16 mg/kg) and/or Formoterol (0.32 mg/kg) Administration:The therapeutic efficacy of co-treatment was investigated in this model over a 56-day-long observation period. Result:COPD assessment test scores were markedly improved in mice with COPD.
-
SynonymsGR-33343X xinafoate
-
PathwayGPCR/G Protein
-
TargetAdrenergic Receptor
-
RecptorWTβ2AR
-
Research AreaInflammation/Immunology
-
IndicationAsthma
Chemical Information
-
CAS Number94749-08-3
-
Formula Weight603.745
-
Molecular FormulaC36H45NO7
-
Purity>98% (HPLC)
-
SolubilityDMSO: ≥ 50 mg/mL
-
SMILESC1=CC=C(C=C1)CCCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O.C1=CC=C2C(=C1)C=CC(=C2O)C(=O)O
-
Chemical Name2-Naphthalenecarboxylic acid, 1-hydroxy-, compd. with 4-hydroxy-α1-[[[6-(4-phenylbutoxy)hexyl]amino]methyl]-1,3-benzenedimethanol (1:1)
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Isogaya M, et al. Mol Pharmacol. 1998 Oct;54(4):616-22.
2. Hu Z, et al. Cell Mol Immunol. 2012 May;9(3):267-75.
3. Sharma M, et al. J Periodontol. 2017 Mar 3:1-17.
molnova catalog
related products
-
(S)-Timolol maleate
A potent non-selective β-adrenergic receptor antagonist with Ki of 1.97 and 2 nM for β1 and β2 receptor, respectively.
-
Tamsulosin
Tamsulosin ((R)-(-)-YM12617 free base) is an alpha1A adrenergic receptor antagonist used for the symptomatic treatment of benign prostatic hyperplasia (BPH).
-
L748337
L748337 is a competitive and potent β3-adrenoceptor antagonist that inhibits the action of β3-, β2-, and β1-adrenoceptors, activates MAPK signaling, promotes phosphorylation of Erk1/2, and inhibits the protective effects of CL316243, and is used in the study of disorders caused by abnormalities of the β3-adrenoceptors.
